ASH

News

FDA starts priority review of BeOne's Venclexta rival

BeOne nears a possible FDA okay for sonrotoclax in mantle cell lymphoma, hoping to be the second BCL-2 inhibitor in the US after AbbVie's Venclexta.

News

Kelonia's in vivo CAR-T data will feature at ASH

Kelonia only started human testing of its in vivo CAR-T therapy for multiple myeloma in August, but will report impressive results at ASH next month.

News

ASH: Sanofi’s Sarclisa carves out a multiple myeloma niche

Sanofi’s anti-CD38 antibody Sarclisa has struggled to make headway against Genmab and Johnson & Johnson’s rival Darzalex since it was first approved for multiple myelo

News

ASH: AZ’s danicopan shows long-term benefit in PNH

New data with AstraZeneca’s oral Factor D inhibitor danicopan have built the case for the drug as an add-on to complement C5 antibodies for the treatment of paroxysmal noc

News

ASH: Pfizer builds case for long-acting haemophilia drug

Pfizer’s once-weekly antibody injection for haemophilia A and B, marstacimab, could be on track for regulatory approvals based on solid results in a phase 3 trial reported

Oncology

After a slow start for expensive CAR-T therapies, drug devel...

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel o

FDA starts priority review of BeOne's Venclexta rival

Kelonia's in vivo CAR-T data will feature at ASH

ASH: Sanofi’s Sarclisa carves out a multiple myeloma niche

ASH: AZ’s danicopan shows long-term benefit in PNH

ASH: Pfizer builds case for long-acting haemophilia drug

After a slow start for expensive CAR-T therapies, drug devel...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

ASH

Editor's Picks